The analysis examined data from 4,890 patients treated through the Veterans Health Administration between 2018 and 2023. All had metastatic hormone-sensitive prostate cancer, meaning their disease had spread beyond the prostate but was still responsive to treatments that suppress testosterone and other androgen hormones. Most patients received testosterone deprivation therapy, also known as androgen-deprivation therapy, either alone or in combination with additional medicines designed to block androgen production or prevent testosterone from activating prostate cancer cells.

PSA is a protein produced primarily by prostate cells. Because prostate cancer cells often release PSA into the bloodstream, doctors routinely measure its concentration to monitor how the disease responds to treatment. A declining PSA level generally indicates that the cancer is becoming less active, while a rising level can signal resistance or progression. However, clinicians have used several different ways to interpret a response, including the percentage reduction from a patient’s starting PSA level and whether the concentration reaches a particular absolute value.

In the new study, the researchers focused on whether reaching a PSA level below 0.2 ng/mL was more closely associated with survival than achieving a decline of at least 90 percent. The 0.2 ng/mL threshold has emerged from several phase 3 clinical trials as a potentially meaningful measure of treatment response, but evidence from everyday clinical practice has been more limited. The investigators therefore used health records from a large national medical system to assess how these response measures performed in a community-based, real-world population.

During a median follow-up period of approximately two years, 896 patients died. Those who reached a PSA level below 0.2 ng/mL within nine months of starting treatment were 54 percent less likely to die than patients who did not reach that level. The association remained whether or not the patients also experienced a PSA reduction of at least 90 percent, indicating that the absolute PSA threshold carried prognostic information beyond the size of the decline alone.

The distinction is important because a dramatic percentage reduction does not always mean that the remaining cancer activity is minimal. For example, a patient whose PSA falls from 20 ng/mL to 2 ng/mL has experienced a 90 percent decline, but the final level remains well above 0.2 ng/mL. By contrast, a patient whose PSA drops from 1 ng/mL to 0.15 ng/mL has achieved a smaller percentage reduction but has reached the lower absolute threshold associated with more favorable outcomes in this analysis.

Patients who experienced at least a 90 percent decline but did not reach a PSA level below 0.2 ng/mL showed no significant survival improvement compared with patients who failed to achieve the 90 percent reduction. This finding suggests that the depth of suppression may be more clinically informative than the relative change from baseline. It also supports the idea that PSA response should be assessed using both the starting value and the level that remains after treatment, rather than relying on percentage decline alone.

The study further found that patients treated with testosterone deprivation therapy plus another androgen-blocking drug were more likely to reach a PSA level below 0.2 ng/mL than those receiving hormone suppression without treatment intensification. Modern combination approaches can inhibit the androgen pathway at multiple points: some medicines reduce testosterone production, while others block the androgen receptor that cancer cells use to receive growth signals. More complete disruption of this pathway may explain why combination therapy was associated with deeper PSA responses.

The findings could help physicians identify patients who may need closer monitoring or earlier treatment escalation. A patient whose PSA remains above 0.2 ng/mL during the first nine months of therapy may have a less favorable response and could be considered for additional treatment strategies, depending on overall health, cancer distribution, symptoms, genomic characteristics, and treatment goals. The researchers emphasize that the study shows an association rather than proving that changing therapy solely to force a lower PSA will extend life. Nevertheless, the results provide a practical target for evaluating response in routine care and reinforce the importance of achieving the deepest possible disease control in metastatic prostate cancer.

“ These data show that we need to target a PSA below 0.2 ng/ml as our metric of success to optimize outcomes for our patients with metastatic prostate cancer,” said corresponding author Stephen J. Freedland, MD, professor of urology at Cedars-Sinai and staff physician at the Durham VA Medical Center. Because the analysis was observational and based largely on Veterans Health Administration patients, future studies will need to determine whether the same threshold applies across broader populations and whether treatment decisions guided by this PSA target can improve survival in prospective clinical trials.

Subject of Research: Metastatic hormone-sensitive prostate cancer and PSA response to androgen-deprivation therapy

Article Title: How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration-sensitive prostate cancer in the Veterans Health Administration data

News Publication Date: August 10, 2026

Web References: CANCER journal: https://acsjournals.onlinelibrary.wiley.com/journal/10970142; DOI: https://doi.org/10.1002/cncr.70494

References: Stephen J. Freedland, Wei Gao, Maëlys Touya, Hongbo Yang, Jingyi Chen, Grace Chen, and Jasmina I. Ivanova. “How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration-sensitive prostate cancer in the Veterans Health Administration data.” CANCER. Published online August 10, 2026. DOI: 10.1002/cncr.70494

Keywords: Prostate cancer, metastatic cancer, PSA, prostate-specific antigen, androgen-deprivation therapy, hormone therapy, testosterone suppression, cancer treatment response, survival, oncology, urology, Veterans Health Administration

NEPC is notorious in oncology for its rapid progression, resistance to conventional androgen deprivation therapies, and a poor prognosis compared to typical prostate adenocarcinomas. Researchers have long struggled to decipher the molecular underpinnings of NEPC, which diverges significantly from its androgen-dependent counterparts. Central to the novel insights presented is the role of cellular stress mechanisms, specifically those emanating from the endoplasmic reticulum, and their crosstalk with the cellular redox environment, which together create a hostile tumor microenvironment conducive to malignant transformation.

The endoplasmic reticulum, a key organelle responsible for proper protein folding and intracellular calcium homeostasis, becomes burdened under conditions of persistent stress, triggering what is known as the unfolded protein response (UPR). This adaptive pathway, when chronically activated, can paradoxically escalate survival signals for cancer cells, allowing them to thrive under conditions that would normally induce cell death. The study meticulously delineates how this ER stress response is intricately linked with alterations in redox signaling, specifically via nitroso-redox imbalance, which exacerbates tumor growth and dissemination in NEPC.

Nitroso-redox imbalance refers to the dysregulation of nitric oxide and reactive oxygen species within the cellular milieu, a phenomenon that has garnered increasing attention due to its dual role in cellular signaling and oxidative damage. Tumor cells exploit this imbalance to evade apoptosis and modulate the immune response, thereby securing a microenvironment that favors unchecked proliferation. The research team has demonstrated that NEPC tumors exhibit pronounced nitroso-redox disequilibrium, underpinning their aggressive phenotype.

Addressing this pathological nexus, the study explores nitric oxide—not merely as a biomolecule with vasodilatory function but as a versatile mediator capable of restoring cellular homeostasis. The authors present compelling evidence that carefully modulated nitric oxide donors can rectify ER stress markers and rebalance the nitroso-redox state in NEPC cells, culminating in suppressed tumor growth and enhanced susceptibility to apoptosis. This dual mechanism represents an elegant therapeutic strategy that simultaneously undermines two cancer-promoting processes.

What sets this study apart is the comprehensive mechanistic approach the researchers adopted. Utilizing advanced molecular biology techniques, they tracked the response of key UPR transducers like PERK, IRE1α, and ATF6 under nitric oxide treatment, revealing attenuated signaling pathways associated with cancer cell survival. Parallel assays quantified shifts in reactive oxygen and nitrogen species, confirming restoration of redox equilibrium. These findings underscore a precise, targeted intervention, as opposed to blanket antioxidant therapies that have previously failed in clinical trials.

The implications extend beyond NEPC itself, as ER stress and nitroso-redox imbalance are pervasive themes in various malignancies. By establishing a direct link between nitric oxide modulation and tumor microenvironment normalization, this research paves the way for broader application of similar strategies across cancer types that share these pathogenic features. It invites a reevaluation of nitric oxide’s role in oncology, potentially repositioning it from a background player to a cornerstone of emerging therapeutic regimens.

Moreover, the therapeutic potential of nitric oxide is enhanced by its inherent biochemical versatility and the availability of diverse nitric oxide donors that can be fine-tuned for targeted delivery. The study hints at the feasibility of designing combination therapies that integrate nitric oxide donors with existing chemotherapeutics or novel agents targeting complementary pathways, thereby overcoming resistance mechanisms endemic to NEPC.

The study also raises intriguing questions that beckon further exploration. For instance, the temporal dynamics of nitric oxide application—whether continuous or intermittent dosing yields optimal outcomes—remain to be established. The interaction between nitric oxide signaling and other intracellular stress cascades, such as mitochondrial dysfunction and autophagy, offers fertile ground for subsequent research, potentially unveiling additional therapeutic targets.

From a clinical perspective, the prospect of leveraging nitric oxide’s capacity to recalibrate ER stress responses and redox balance introduces an innovative dimension in patient management. Biomarker development to monitor nitroso-redox status and ER stress levels in NEPC could enable personalized treatment strategies, tailoring nitric oxide-based interventions to individual tumor profiles and disease stages, thereby maximizing efficacy and minimizing adverse effects.

This advancement also signals progress in overcoming one of the enduring challenges in prostate cancer treatment—tackling the neuroendocrine phenotype that often emerges following androgen deprivation therapy resistance. The ability to disrupt supportive stress and redox pathways integral to NEPC pathobiology opens new therapeutic corridors that might extend patient survival and enhance quality of life.

The research draws attention to the intricate biochemical symphony playing out within cancer cells, reminding us that effective cancer therapy hinges not merely on destroying cells but on recalibrating the cellular ecosystem. Nitric oxide’s therapeutic role in this context exemplifies the sophistication of next-generation cancer treatments, where molecular precision and pathway-specific modulation form the heart of clinical innovation.

As the scientific community anticipates validation of these findings through clinical trials, the foundational work presented sets a high benchmark for future oncology research. The nuanced interplay of ER stress, redox signaling, and nitric oxide’s regulatory functions constitute a promising triad in the fight against NEPC, heralding a paradigm shift in how we approach treatment-resistant prostate cancers.

This study’s integrative approach, combining molecular insights with therapeutic innovation, captures the zeitgeist of contemporary oncology—where understanding cellular stress responses and metabolic imbalances offers the key to unlocking stubborn therapeutic resistances. The use of nitric oxide donors to target these vulnerabilities highlights an emerging therapeutic frontier that could transform patient outcomes significantly.

In conclusion, the elucidation of nitric oxide as a modulator of ER stress and nitroso-redox imbalance in neuroendocrine prostate cancer marks a watershed moment in cancer biology and therapy. This research exemplifies how unraveling complex cellular stress networks can lead to practical, effective treatments, reaffirming the promise of precision medicine in overcoming some of the most formidable challenges in oncology.

Subject of Research: The role of endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer and therapeutic targeting using nitric oxide.

Article Title: Targeting endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer: the therapeutic role of nitric oxide.

Article References:
Firdaus, F., Napoles, O.C., Dulce, R.A. et al. Targeting endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer: the therapeutic role of nitric oxide. Cell Death Discov. 11, 502 (2025). https://doi.org/10.1038/s41420-025-02774-5

Image Credits: AI Generated

DOI: 06 November 2025

Prostate cancer stands as one of the most formidable challenges in contemporary oncology, ranking among the leading causes of cancer-related deaths in men worldwide. In Brazil alone, more than 40 men lose their lives daily to this menacing disease. A significant obstacle in effectively managing prostate cancer lies in its varying aggressiveness; while some cases remain indolent, others progress aggressively, rendering timely prediction essential for better patient outcomes. The researchers aimed to uncover the genetic anomalies that could serve as harbingers of high-risk cases, thereby empowering healthcare professionals to make informed decisions regarding patient care.

The investigation centered on five pivotal genes whose activities are frequently linked to the progression of prostate cancer. The androgen receptor (AR) is a central player in male sexual development and has a profound influence on prostate cancer dynamics. The variant AR-V7, known for its association with castration-resistant prostate cancer (CRPC), presents a significant challenge in treatment, as the cancer continues to advance despite the implementation of androgen suppression therapies. The team also scrutinized the p160 gene family, including SRC-1, SRC-2, and SRC-3, which acts as co-activators of AR, ultimately affecting the aggressiveness of the cancer.

For the study, researchers meticulously analyzed a cohort of 155 patients who underwent radical prostatectomy—surgical removal of the prostate—between 1994 and 2012. They also included tissue samples from 11 healthy individuals to serve as a control mechanism. Utilizing quantitative polymerase chain reaction (qPCR), a sophisticated technique aimed at amplifying and measuring DNA or RNA levels, the scientists quantified the expression levels of the targeted genes in the tissue samples. This robust analysis aimed to elucidate the relationship between genetic expressions and significant clinical characteristics, including cancer recurrence and progression to the far more lethal CRPC.

The study’s findings reveal compelling differences in gene expression levels between cancer patients and the control group. With the exception of SRC-1, all assessed genes demonstrated markedly higher activation levels in the prostate cancer cohort. Despite SRC-1 not achieving statistical significance, its average expression remained elevated among cancer patients, indicating its potential as a relevant marker for metastatic cancer progression. This underscores the need for further exploration of SRC-1’s role and its implications in predicting prostate cancer outcomes.

Intriguingly, the data indicated that AR gene expression did not appear to correlate directly with the expression levels of its auxiliary genes, SRC-1, SRC-2, and SRC-3. However, the variant AR-V7 displayed a robust association with the p160 family genes, particularly SRC-3. This association suggests that AR-V7’s capacity to enable prostate cancer cells to elude hormone therapy is conditional upon the actions of these auxiliary genes. This relationship is significant, as it offers an avenue for developing targeted therapeutic strategies that could mitigate resistance to treatment.

Moreover, the analysis revealed that SRC-2 and SRC-3 are significantly linked with high-risk prostate cancer forms, a critical finding as such categories are more prone to aggressive behavior and poor patient outcomes. Alarmingly, the study discovered that heightened levels of AR activation are associated with a staggering 73.2% increase in the risk of early cancer recurrence. Furthermore, elevated AR-V7 expression corresponded with a 62.1% increase in early recurrence risk. These findings underline the pivotal role that androgen signaling plays in not only the recurrence of prostate cancer but also the development of tumor aggressiveness.

In light of these compelling findings, the researchers posit that these genes could hold promise as prognostic biomarkers for prostate cancer. While SRC-1 showcased distinct activation in metastatic cases, changes in the expression levels of SRC-2 and SRC-3 could provide crucial insights into identifying more aggressive malignancies. These observations carry weighty implications for clinical practice, particularly in enhancing individualized treatment approaches tailored to specific genetic profiles.

The authors of the study stress that while the correlations observed warrant recognition, they also highlight the necessity for ongoing research. Specifically, the intriguing association between SRC-3 and AR-V7 should be a focal point for future investigations, as it could yield profound insights into the role of p160 family proteins in the progression of CRPC. Such inquiries could fundamentally change the landscape of prostate cancer treatment, aligning efforts towards personalized medicine that could significantly improve patient prognoses.

As this study indicates, the journey of understanding prostate cancer is far from over. The complex genetic interplay outlined in this research sheds light on potential pathways that could revolutionize how clinicians approach diagnosis and treatment. The importance of AR, AR-V7, and the p160 co-regulators cannot be understated, as they may pave the way for groundbreaking advancements in personalizing cancer therapy and managing treatment-resistant cases more effectively.

In addition to serving as potential prognostic indicators, these genetic markers could facilitate earlier detection of high-risk patients, thereby prompting timely intervention strategies that could mitigate the lethality of aggressive prostate cancer forms. The implications of this research extend beyond academic inquiry; they signal a paradigm shift within the realm of oncology that emphasizes genetic profiling as a cornerstone of cancer therapy, possibly yielding innovative treatment modalities that resonate with each patient’s unique genetic makeup.

In conclusion, the insights gained from this study not only contribute to the broader body of knowledge surrounding prostate cancer but also carry significant implications for the future of cancer research and treatment methodology. The correlations established between gene expression and clinical outcomes are emblematic of the intricate relationship between genetic factors and cancer progression, emphasizing the need for ongoing investigation into how we can leverage this understanding to enhance patient care and achieve better outcomes in the battle against prostate cancer.

Subject of Research: Genetic predictors of prostate cancer progression
Article Title: Unraveling Genetic Predictors of Prostate Cancer Progression
News Publication Date: October 2023
Web References: NCBI Study
References: 10.1007/s00432-023-05598-x
Image Credits: Journal of Cancer Research and Clinical Oncology

Keywords: Prostate cancer, Cancer research, Disease progression, Clinical research, Protein expression, Gene prediction, Cancer genetics, Androgen signaling